mellowsong
03-30-12, 06:34 PM
Marlene Busko
30 March 2012
Drug companies should be required to submit phase 2 or 3 data to rule out excess cardiovascular risk for new obesity drugs that do not have signs or potential for precipitating cardiovascular events, FDA advisors say.
Members of the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 17 to 6 in favor of these requirements, after much discussion evaluating the implications of this new approach. The meeting was restricted to focusing on obesity drugs without a theoretical risk or signal for cardiovascular harm.
Read more: http://www.medscape.com/viewarticle/761266
30 March 2012
Drug companies should be required to submit phase 2 or 3 data to rule out excess cardiovascular risk for new obesity drugs that do not have signs or potential for precipitating cardiovascular events, FDA advisors say.
Members of the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 17 to 6 in favor of these requirements, after much discussion evaluating the implications of this new approach. The meeting was restricted to focusing on obesity drugs without a theoretical risk or signal for cardiovascular harm.
Read more: http://www.medscape.com/viewarticle/761266